| Added by | JPPOUGET |
|---|---|
| Group name | EquipeJPP |
| Item Type | Journal Article |
| Title | Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors |
| Creator | Pouget et al. |
| Author | Jean-Pierre Pouget |
| Author | Timothy A. Chan |
| Author | Lorenzo Galluzzi |
| Author | Julie Constanzo |
| Abstract | Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple cancer types. However, only a fraction of patients with cancer responds to ICIs employed as stand-alone therapeutics, calling for the development of safe and effective combinatorial regimens to extend the benefits of ICIs to a larger patient population. In addition to exhibiting a good safety and efficacy profile, targeted radionuclide therapy (TRT) with radiopharmaceuticals that specifically accumulate in the tumor microenvironment has been associated with promising immunostimulatory effects that (at least in preclinical cancer models) provide a robust platform for the development of TRT/ICI combinations. We discuss preclinical and clinical findings suggesting that TRT stands out as a promising partner for the development of safe and efficient combinatorial regimens involving ICIs. |
| Publication | Trends in Cancer |
| Volume | 9 |
| Issue | 11 |
| Pages | 968-981 |
| Date | 2023-11 |
| Journal Abbr | Trends Cancer |
| Language | eng |
| DOI | 10.1016/j.trecan.2023.07.014 |
| ISSN | 2405-8025 |
| Library Catalog | PubMed |
| Extra | PMID: 37612188 PMCID: PMC11311210 |
| Tags | Antineoplastic Agents, Immunological, external beam radiation therapy, first-last-coresponding, Humans, immunogenic cell death, Neoplasms, pembrolizumab, Radiopharmaceuticals, review, top, Tumor Microenvironment |
| Date Added | 2024/12/07 - 07:04:10 |
| Date Modified | 2024/12/07 - 07:12:58 |
| Notes and Attachments | Accepted Version (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
